Celgene Corporation (NASDAQ:CELG) today announced that data from
FIRST (MM-020/IFM 07-01)—an open-label phase III randomized study of
continuous REVLIMID (lenalidomide) in combination with dexamethasone in
patients newly diagnosed with multiple myeloma (NDMM) who are not
candidates for stem cell transplant—have been published in the Sept.
for Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine investment picks